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A controlled trial of cyclosporine in patients with progressive membra.
nous nephropathy. A controlled trial of cyclosporine in patients diagnosed
with progressive membranous nephropathy (MGN) was carried out to
determine whether cyclosporine (D) would be more effective than placebo
(F) in reducing the rate of deterioration in renal function. Patients (N =
64) with MGN were placed on a restricted protein diet ( 0.9 gikg) and
followed closely for 12 months (Part 1). Patients at high risk of progression
based on an absolute loss in creatinine clearance (Car) of  8 ml/min and
persistent nephrotic range proteinuria (Pr) were selected and randomly
assigned to either (D) (N = 9) or (P) (N = 8) for 12 months (Part 2). No
differences in the two groups were noted at entry. After 12 months, the
improvement in Cr slope in mi/mm/month was significantly greater in the
D patients (D + 2.1 vs. P + 0.5, mean difference 1.6; 95% CI 0.3 to 3.0,
P < 0.02). This improvement was maintained in six of eight D (75%) over
a mean follow-up period of 21 months. Daily Pr also improved with D (by
month 3, D — 4.5 g/day vs. P + 0.7 g/day, P = 0.02) and was sustained in
six of eight (75%) D patients. When Pr was expressed as a function of their
concurrent Ce,, the D versus P patients' time to halving was faster (P =
0.02) and absolute number higher (4/9 D vs 0/8 P). In the D group a trend
towards worse hypertension and an increase in the number of transient
rises in serum creatinine were noted. In progressive MGN, D is often
effective in reducing both the rate of renal deterioration and Pr. These
benefits extended for up to two years post-treatment.
Worldwide, idiopathic membranous nephropathy is the most
common cause of the nephrotic syndrome in adults and remains
responsible for up to 6% of all cases of ESRD due to primary
giomerulonephritis [1—6]. Controlled prospective clinical trials in
unselected patients with this disorder using either steroids alone
[7—9] or cyclophosphamide alone [10] have shown marginal or no
effect, although when prednisone is combined with chiorambucil a
benefit has been demonstrated [11—13]. However, concerns about
the long-term risks of such a drug combination, coupled with the
recognition that up to one third of patients will spontaneously
remit, has limited the utilization of this therapy. An alternate
approach has been to treat only patients felt to be at high risk of
progression. These studies have been uncontrolled with consider-
able variability in both the selection criteria and results [14—18].
The exception was a recently published controlled trial by Falk et
al which failed to demonstrate any additional benefit when
cyclophosphamide plus steroids was compared to a steroid-only
treatment group [19].
Cyclosporine is a potent immunosuppressive agent that has
been used in an uncontrolled fashion and in a limited number of
patients with idiopathic membranous nephropathy but with en-
couraging results [20—24]. We report the results from our con-
trolled long-term trial which compared cyclosporine treatment to
placebo in a group of patients with this disorder, who had
prospective documentation of progressive deterioration in renal
function.
Methods
Part 1
All recent ( 24 months) biopsy-proven cases of membranous
nephropathy in patients aged 18 to 65 with proteinuria  1 g/day
were eligible for the 12 month observation section of the study
(Part 1). Exclusion criteria were clinically apparent or drug
related secondary causes or laboratory evidence of hepatitis,
disseminated lupus esythematosus or diabetes mellitus. After
signing an informed consent, approved by each institution's review
board all patients were placed on a 0.9 g/kg restricted protein,
 90 mmoliday sodium diet, and the observation begun. The
blood pressure target in all patients was  140/90 mm Hg supine,
but the choice of agents as well as diuretic type and dose were at
the discretion of the individual nephrologist. Monitoring of their
clinical state, blood pressure and edema status, as well as labora-
tory tests including serum creatinine, electrolytes, urea, albumin
and 24-hour urine estimates of urea, protein content and creati-
nine were required every four weeks. Absolute loss of function
from baseline and the rate of deterioration in renal function as
measured by the change in both creatinine clearance in mi/mini
month and by reciprocal of creatinine were estimated by our
registry computer program. It calculated a slope on each patient
based on these laboratory tests and the elapsed time from study
entry. The first slope was not done until a minimum of four points
based on these monthly tests had been received.
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Part 2
Any patient whose calculations between the fourth and twelfth
month of Part 1 showed both a consistant and an absolute decline
in Cr of  8 mi/mm and whose proteinuria remained at  3.5
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Table 1. Patient characteristics at ently to Part I (N = 64)
Age (range) 47 (19—65)
Gender
Males 47
Females 17
Creatinine juno//liter 127 49
Creatinine clearance mI/mm/i. 73 m 77 29
Proteinuria g/daya 6.4 (1.1—23.9)
Albumin g/liter 30.6 7.2
Blood pressure mm Hg
Systolic 133 17
Diastolic 82 10
Data are mean SD.
a Median (range)
g/day was eligible for Part 2. Exclusion criteria were the same as
Part 1 plus if the patient had any serious co-morbid medical
condition at the point of eligibility or their creatinine clearance
was  30 ml/min. No corticosteroids, immunosuppressive drugs or
nonsteroidal anti-inflammatory agents were allowed during Part 1.
If on review no reversible cause such as infection, drug therapy, or
volume depletion from diuretics was noted, the patient was asked
to participate in Part 2. A separate, approved informed consent
was required prior to entry into this section of the trial.
The patients were randomly assigned to either cyclosporine (D)
or placebo (P) in blocks stratified by center. The patients were
masked in regards to their assignment, but for safety reasons the
physician in charge was not. In addition to Part 1 tests, whole
blood monoclonal immunoassayed cyclosporine trough levels and
liver function estimates were monitored at 1, 2, 4, 6 and 8 weeks,
and then monthly for 10 months. The same clinical and laboratory
observations as in Part 1 were then performed every second
month until death (N = 1), initiation of dialysis (N = 5), or censor
date of study.
Liquid cyclosporine, 100 mg/mI, was initiated at 3.5 mg/kg/day
taken in two divided doses, and periodic adjustments were made
as necessary to achieve a 12-hour trough level of between 110 and
170 jig/liter. The placebo was made of the identical carrier except
cyclosporine was excluded. It was initially prescribed at 0.035
mI/kg/day, taken in two divided quantities with periodic arbitrary
adjustments in dose to match the cyclosporine group.
The hypertension control goal was 140/90 mm Hg. The
choice of agents was that of the patient's nephrologist, except no
angiotensin converting enzyme inhibitors were allowed unless the
patient had been on such therapy a minimum of three months
prior to Part 2 entry.
A diagnosis of membranous nephropathy by the local patholo-
gist based on light, immunofluorescence and electron microscopy
was sufficient for entry to Part 1. All the renal pathology for
patients who entered Part 2 was subsequently independently
reviewed by a nephropathologist (SR) who was unaware of the
patient's group assignment. The pathology was graded both by the
classic staging method [25] and by an estimate of the degree of
glomenilar obsolescence, interstitial fibrosis and infiltrate, tubular
atrophy, and vascular changes. The latter four were all scored on
a scale of 0 to 4+ (none, mild, moderate or severe).
Stop points
If the creatinine rose  30% above the Part 2 entry value and
remained so despite a 50% reduction in test medication and
Table 2. Patient characteristics at entry to Part 2
Cyclosporine
group,N= 9
Placebo
N= 8
Age (range) 44 (22—59) 40 (20—61)
Number of males (%) 8 (89) 6 (75)
Creatinine juno//I]' 186 65 204 81
Ccr mI/mm/i. 73 m2a 51 20 46 16
Proteinuria g/day' 11.5 (9—18) 12.8 (4—21)
Serum albumin g/litera 29 6.6 30 9.2
Systolic BP mm Hga 141 6 138 16
Diastolic BP mm Hga
Ultra structural stageb
Interstitial fibrosis (Q_4±)b
Tubular atrophy (0_4+)"
82 12
2.2 (1—4)
0.9 (0—1)
0.7 (0—2)
83 7
2.0 (1—4)
0.4 (0—1)
0.3 (0—2)
Observation period in monthsc
Part 1 9.3 (6—13) 9.7 (7—12)
Part 2 10.1 (4—13) 8.9 (4—13)
Post-med. 20 (0—41) 22 (6—56)
Total 49 (17—75) 48 (25—88)
a Mean SD
b Median (range)
Mean (range)
adjustments in diuretic dose if intravascular volume was a con-
cern, and a two week wait, the study drug was discontinued. Other
stop points were a potassium> 6.0 mEq/liter, a doubling of entry
value liver function tests, at the patient's request, or if complete
remission of proteinuria occurred.
Statistical analysis
The primary end point was the difference in the D versus P
groups change in renal function as measured by the slope of C.
in ml/min/month after 12 months in Part 2 compared to Part 1.
Since certain events could create an early stop point, the same
analysis was repeated using the end point as the actual time the
test medication was discontinued in any patient. Analysis was by
both Wilcoxon and by Student's f-tests. Values in the tables are
means SD unless otherwise indicated.
Other statistical tests used included Chi square tests for pro-
portions and the nonparametric Mann Whitney rank sum test for
comparing changes in proteinuria and standardized proteinuria(this latter term was the value of the 24-hour urine protein
expressed in p.g/min divided by the concurrent Cr in ml/min). All
tests were two tailed. Kaplan-Meier survival curves and the log
rank test were used to look at time to events and remission of
proteinuria rates. (SAS Institute, Inc.; Cary, NC, USA.)
Results
Sixty-four patients entered Part 1 and had a minimum of four
months of observations. There were 47 males and 17 females with
a mean age of 47.4 years, range, 19 to 65. There were 56 (87%)
Caucasian, 1 (2%) Black, 2 (3%) Asian and 5 (8%) patients of
mixed racial origin. Other clinical and laboratory characteristics at
Part 1 entry are outlined in Table 1. The mean months of
observation in Part I was 10.6 with a range between 4 and 13.
Twenty-three patients fulfilled all of the Part 2 criteria, but
three refused the study, one had sepsis as an explanation for
decline in function, one was noncompliant and one had a level of
renal function too low to risk cyclosporine therapy. Seventeen
patients were thus eligible and consented to randomization.
Sixteen were Caucasian and one was Asian. Other demographic
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Patients randomized Number Part 1 Part 2 z
Cyclosporine 9 —2.4 (1.4) —0.7 (1.0)
Placebo 8
—2.2(1.1) —2.1(1.6) 0.1
Non-randomized 47
—0.5 (1.5) — —
a Period while on medication
hp < 0.02 vs. placebo
—5.
—6
and renal function characteristics are depicted in Table 2. No
differences in clinical, laboratory or pathology features were
observed at entry between the two groups.
The average nonrandomized patients' monthly slopes in C.n
Part 1 were significantly less negative and more stable than the
patients selected for Part 2 (—0.5 vs. —2.3, P < 0.005) and their
slopes remained stable in a subsequent year of follow-up (—0.3)
(Table 3). The overall rate of deterioration in the placebo patients
in mi/mm/month was unchanged in Part 1 versus Part 2 (—2.18 vs.
—2.05; Fig. 1) but a significant improvement was seen in the
cyclosporine patients (—2.43 vs. —0.73, P < 0.02; Fig. 2). The
improvement in renal function as measured by the change in
slopes (Part 2 on medication minus Part 1) was also greater in the
D versus P patients in both absolute and percentage terms [D +
1.7 (70% improvement) vs. P + 0.1 (7% improvement), mean
difference 1.5 (95% CI 0.2 to 3.1)1 (Table 3). When examined by
nonparametric methods to account for the variations in slope, the
P value remained unchanged (P < 0.02). This improvement was
maintained at 12 months [D + 2.1 (88%) vs. P + 0.5 (23%), mean
difference 1.6 (95% CI 0.3 to 3.0)]. When the same statistical tests
were applied to the slopes of the reciprocal of creatinine, the
results and P values were the same.
Proteinuria in the D group was reduced by an average of 4.5
g/day versus P group increase of 0.7 g/day by month 3, P = 0.02.
This overall improvement was maintained until the last follow-up
(4.5 g/day vs. 9.2 g/day, P = 0.03; Table 4). Halving of proteinuria
was seen in four of eight D versus none of eight P. In an attempt
to account for the rapid changes in glomerular filtration rate, daily
proteinuria was expressed as a function of the concurrent creati-
nine clearance (Fig. 3). A significant improvement was seen in the
D patients in both the time to (P < 0.02) and the number (6/8 D
vs. 0/8 P) who halved their standardized proteinuria, and this
particular marker of improvement persisted until their last fol-
low-up in six of eight D versus zero of eight P.
The mean dose of cyclosporine was 3.8 mg/kg with a range
between 2.5 and 4.9. An automatic dose reduction was reached
because of a  30% rise in serum creatinine above Part 2 entry in
10 patients (6 D, 4 P) but with medication adjustment, this
reversed in five D but none in P. One D patient died following an
unrelated acute myocardial infarction after five months of treat-
ment. His latest function prior to death showed improved pro-
teinuria from 17.8 g/day at entry to 3.8 g/day prior to his death.
Even if this patient's slope was projected to 12 months, the
improvement in D versus P C slope in Part 2 remained
significant.
Post-test medication observations were continued for a mean of
21 months. Seven of eight D patients maintained their improved
slope compared to Part 1 until their last follow-up 21 to 50 months
post-medication. One patient deteriorated to the point of dialysis
14 months after the medication was discontinued. Deterioration
continued in seven of eight P patients, with four patients requiring
dialysis after an average follow-up of 10.0 months (range 0.5 to 18;
Fig. 4).
Four patients (D2, P2) required the addition of antihyperten-
sive therapy in Part 2 and the requirements increased in five other
patients (D4, P1). None of the newly diagnosed hypertensive
patients were given ACE inhibitors, and those on this therapy in
Part 1 (Dl, P1) had no change in dosage during Part 2. Although
there was a trend to a greater number and severity of hypertensive
problems in the cyclosporine treated patients (P = 0.9), they were
all maintained below the prescribed target of 140/90 mm Hg.
Mean arterial pressure, based on monthly measurements was not
different between D and P groups in Part 1 or Part 2. Other
adverse effects were equal in the two randomized groups with
respect to gastrointestinal complaints (D2, P1), tremor (Dl, P1),
hirsutism (Dl, P1), and infections (Dl, P3). No malignancies were
seen in any patient. Dietary compliance to the 0.9 g/kg protein
restriction was checked by monthly urine urea quantitation and
adherence noted in  80% of visits. Only two patients (Dl, P1)
were assessed as noncompliant in that their urine ureas indicated
a dietary protein intake  30% above that prescribed in more
than 20% of visits.
Discussion
The natural history of membranous nephropathy is variable
with 10 to 45% reaching chronic or end-stage renal failure 5 to 10
Table 3. Slopes of creatinine clearance (mi/mm/month)
1
0
—1
—2
—3
-4
0
-1
E -2
5E-4
—5
—6
Fig. 2. Slope of creatinine clearance in mI/mm/month in all cyclospormne
patients in Part 1 compared to Part 2 (LI). Solid, longer bar is the mean
change in slope between pretest and cyclosporine medication.o
oE
CoCD-.
wE
Partl Part2
Partl Part2
Fig. 1. Slope of creatinine clearance in mI/mm/month in all placebo patients
in Part 1 compared to Part 2 (*). Solid, longer bar is the mean change in
slope between pretest and placebo medication period.
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Table 4. Proteinuria and serum albumin data in both study groups
Proteinuria giday Serum albumin glliter
Cyclosporine Placebo Cyclosporine Placebo
Entry
Month 3
Month 12
Last follow-up
11.5 3
7.0 4
7.9 7
4.5 4"
12.8 4
13.5 9
11.0 5
9.2 5
29.2 7
33.9 4
34.8 4
33.6 4
29.7 9
30.5 9
31.6 9
33.4 7
A
Data are mean
P = 0.02
bp = 0.03
SD.
A
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Fig. 3. Daily proteinuria expressed as a fimction of the patients' concunent
glomerular filtration rate (p.g per ml of creatinine clearance) in the two
treatment groups. Plots begin during the Part 1 observation period (months
with — sign) and continue during the test medication period (0—12
months) and to censor point, death (V) or dialysis (•), inboth groups. The
cyclosporine patients are in A, solid lines (—) and the placebo patients
are in B, broken lines (- -
years after presentation [1—5, 26—29]. The majority of controlled
therapeutic trials in this disorder have had very few entry restric-
tions [7—9] or have limited the trial to those with the best function
[11—13]. Two recent studies using steroids alone demonstrated no
benefit [8, 9], and although a combination of a cytotoxic drug plus
corticosteroids has been shown to be effective [12], the recogni-
tion that many of these patients would have been stable or
110
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Months from randomization
Fig. 4. Creatinine clearance measurements in all patients in the two treat-
ment groups. Plots begin during the Part 1 observation period (months with
—
sign), continue during test medications (0—12 months) and post-
medication to censor point, death (A) or dialysis (•), in both groups. The
cyclosporine patients are in A, solid lines (—) and the placebo patients
are in B, broken lines (- -
improved without treatment has limited widespread application of
this regimen.
Our study prospectively selected a high risk group for our test
medication trial from a base of patients with typical idiopathic
membranous glomerulonephritis. The patients who were not
eligible for Part 2 had and continued to maintain a relatively
nonprogressive course during and post-Part 1, with an average
annual loss of function between 0 and 6%. This was in contrast to
our randomized patients' annual loss of between 26 and 29%
during Part 1. The randomized patients at entry to Part 2 had
other well-recognized risk factors associated with a poor progno-
sis, including both heavy proteinuria (median value 12.2 glday),
and elevated creatinine (mean value 195 mo1/liter) [1—4, 26—29].
There were no statistical or clinical differences between the D
and P patients at Part 2 entry (Table 2). After 12 months the
cyclosporine treated patients showed an overall 88% slowing in
their rate of decline of creatinine clearance compared to 23% in
the placebo group. This improvement persisted for up to 40
months after the medication was discontinued in seven of eight
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(88%) D patients. The clinical relevance of the benefit of treat-
ment is emphasized by the overall outcome. The CCr at Part 2
entry was similar in P versus D (46 ml/min vs. 51 mI/mm, P NS)
but by two years six of eight P had progressed to less than 30%
residual function (4 ESRD) compared to only two of eight in the
D group (1 ESRD), with the remaining six averaging a C. of 45
mI/mm. Proteinuria was also significantly improved by cyclospo-
rine (Table 4), and although it rose transiently after the drug was
discontinued in three patients, at last follow-up one D patient had
normalized his proteinuria, six remained at less than 50% of their
Part 2 entry value and two patients were unchanged. Decreasing
proteinuria associated with a parallel decline in Cr is not
indicative of a drug benefit. Proteinuria was therefore also
expressed in terms of the patients' concurrent creatinine clear-
ance. The time to halving of this ratio should more accurately
reflect absolute improvement in glomerular permeability to pro-
tein because it accounts for changes in glomerular filtration rate.
The time to this event was reduced in D patients compared to the
P group (P < 0.02) and this marker of improvement remained
beyond the test medication period in six of eight (75%) D patients
versus none of the P group (Fig. 3).
There are more precise techniques for measuring the changes
in glomerular filtration rate than creatinine clearance [301. How-
ever, repeated measures, length of follow-up, plus utilization of
the patients as their own controls, help to limit this problem [31,
32]. As well, no major intercurrent illnesses or purposeful loss of
lean body mass of more than 10% was seen in any patient in Part
2. Thus, fluctuations in urine creatinine due to loss of muscle mass
was not an issue. Obtaining similar results when the reciprocal of
serum creatinine slopes were compared also helps strengthen our
conclusions. Moreover, since a significant part of the error in C
measurements, as filtration function fails, is due to the increased
percentage of urine creatinine attributable to the amount of its
tubular secretion, the overestimates of function should be greatest
in patients with the lowest Car. This should bias against the D
group since the P patients by the end of Part 2 had much lower
Ccr values. This may well have been the explanation for an
apparent slowing in the rate of decline in creatinine clearance in
several of the P patients in their predialysis phase. Earlier
uncontrolled studies have suggested there is improvement in both
severity of proteinuria and stabilization of Cr in some MGN
patients treated with cyclosporine [20—24, 33, 341. Although the
precise mechanism of its effect is unknown, recent data indicates
a direct immunologic benefit of the drug on both glomerular
barrier function and systemic cytokine levels in patients with
MGN [24, 35]. There are, however, potential risks to this medi-
cation. Hypertension was more common in the D patients, but was
readily controlled and the mean arterial pressure was equal in the
two groups throughout the study. No patients required additional
treatment with ACE inhibitor class medication. This data would
support our contention that neither the hypertension control nor
ACE inhibitor class drugs, indicated by some to improve protein-
uria in MGN patients [36], are the explanation for our observed
results. Compliance to dietary protein restriction was equal in the
two groups and is also therefore unlikely to be the explanation for
the improvement observed. The only other significant adverse
effect of cyclosporine was on serum creatinine concentration.
Although the number of transient rises  30% above baseline was
greater in the D patients (6 vs. 4), it was reversed in five of six
(83%) of the D cases by a temporary reduction in dose, whereas
medication reduction did not lead to improvement in any of the P
patients. This suggests a major component was a drug-induced
hemodynamic effect in the D patients versus the natural history of
the disease as the explanation in the P patients. This is an
important safety issue since we and other authors have suggested
that the amount of cyclosporine should be adjusted down if
creatinine rises in order to minimize the risk of long-term drug
induced nephrotoxicity [20, 37]. Our mean and range of cyclospo-
rine drug usage were where minimum chronic damage has been
reported. The maintenance of the improved slope in Cr for up to
two years post-cyclosporine would also indicate that we were in
the safe drug dose range.
Previous authors have selected patients at high risk of progres-
sion in a number of different ways and then applied a variety of
therapeutic agents. These drug routines have included pulse
methylprednisolone [16], combined chiorambucil and corticoste-
roids [14, 15], prolonged cyclophosphamide plus other agents [17,
18, 38—401 and even intravenous immunoglobulin G [41]. The
results have varied and have sometimes been contradictory [14,
151. All have been uncontrolled. The need for a placebo group is
underlined by the variations we observed even in our P patients
despite our stringent selection criteria (Figs. 1 and 4). This is
further emphasized by the variation seen in the only other
published controlled trial in preselected high risk patients [19].
We recognize that the numbers in the randomized section of
the trial are small. However, our selection criteria were rigid and
followed established criteria that have been shown to accurately
predict those patients most likely to progress to chronic renal
insufficiency [26]. This type of selection both permits conclusions
to be drawn from much smaller numbers and avoids needless
treatment with potentially toxic drugs in patients who would do
well with symptomatic management alone. Support for this type of
preselection to improve the risk-benefit ratio of treatment has
been the subject of two recent editorial reviews [42, 43].
Whether reduced nephrotoxic risk but equal immunosuppres-
sive effect could be obtained by either a shorter course or lower
dose of cyclosporine than the routine used is unknown and needs
further study. Similarly, if additional benefits could be derived by
its use at an earlier stage of the disease needs to be addressed.
However, our results do suggest that with careful monitoring, a
course of cyclosporine is safe and often effective in both slowing
the rate of decline in function and improving proteinuria in
patients with proven progressive membranous nephropathy. Our
data further suggest that this effect may persist for a considerable
period even after the medication is discontinued.
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